Publications by authors named "F O Balogun"
Nearly all pancreatic adenocarcinomas (PDAC) are genomically characterized by KRAS exon 2 mutations. Most patients with PDAC present with advanced disease and are treated with cytotoxic therapy. Genomic biomarkers prognostic of disease outcomes have been challenging to identify.
View Article and Find Full Text PDFArticle Synopsis
- Adjuvant mFOLFIRINOX (mFFX) is a standard treatment for patients with resected pancreatic ductal adenocarcinoma (PDAC), but there is limited information on its effectiveness outside of clinical trials.
- A study of 147 patients showed a median recurrence-free survival (RFS) of 26 months, with some patients over 70 years experiencing a median overall survival (OS) of 51 months.
- Starting mFFX treatment within 8 weeks of surgery was linked to better survival outcomes, while certain genetic factors like KRAS mutations suggested poorer RFS and OS.
Article Synopsis
- The study investigates the role of microsatellite instability (MSI-H) in pancreatic cancer (PC) associated with Lynch syndrome (LS), focusing on both germline and somatic variants that affect mismatch repair genes.
- It involves a retrospective analysis of 55 PC patients at Memorial Sloan Kettering Cancer Center, revealing that a significant portion of those with LS and somatic MMR variants exhibit MSI-H status, which could impact treatment responses to immune therapy.
- Results showed that 59% of LS cohort patients had MSI-H, whereas 43% in the somatic MMR cohort had the same status, suggesting distinct genetic characteristics and age differences at diagnosis between the two groups.
Objectives: This study compared the infant vaccination trends a year before and a year after the onset of the COVID-19 pandemic in selected urban and rural communities in Ibadan, Nigeria.
Design: This was a cross-sectional study in which data were extracted from infant vaccination records.
Setting: Two rural and three urban vaccination centres in primary health clinics at Ibadan Southeast and Olúyòlé local government areas, respectively.
Background: Mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most common oncogene alteration in pancreatic ductal adenocarcinoma, and KRAS glycine to cystine substitution at codon 12 (G12C) mutations (KRAS G12Cmut) are observed in 1%-2%. Several inhibitors of KRAS G12C have recently demonstrated promise in solid tumors, including pancreatic cancer. Little is known regarding clinical, genomics, and outcome data of this population.
View Article and Find Full Text PDF